Sentinel Lymph Node Biopsy in Cutaneous Melanoma, a Clinical Point of View

Sentinel lymph node biopsy (SLNB) is a surgical procedure that has been used in patients with cutaneous melanoma for nearly 30 years. It is used for both staging and regional disease control with minimum morbidity, as proven by numerous worldwide prospective studies. It has been incorporated in the...

Full description

Saved in:
Bibliographic Details
Published in:Medicina (Kaunas, Lithuania) Lithuania), 2022-11, Vol.58 (11), p.1589
Main Authors: Brănişteanu, Daciana Elena, Cozmin, Mihai, Porumb-Andrese, Elena, Brănişteanu, Daniel, Toader, Mihaela Paula, Iosep, Diana, Sinigur, Diana, Brănişteanu, Cătălina Ioana, Brănişteanu, George, Porumb, Vlad, Pînzariu, Alin Constantin, Băilă, Sorin Liviu, Nicolescu, Alin Codruț
Format: Article
Language:English
Subjects:
Biopsy
Cancer therapies
Care and treatment
clinical guidelines
cutaneous melanoma
Diagnosis
Disease
Hematoma
Humans
Localization
Lymph nodes
Lymphatic system
Lymphedema
Medical prognosis
Melanoma
Melanoma - surgery
Melanoma, Cutaneous Malignant
Metastasis
Neoplasm Staging
Practice guidelines (Medicine)
Prospective Studies
Review
Risk factors
Sentinel Lymph Node - pathology
sentinel lymph node biopsy
Sentinel Lymph Node Biopsy - methods
Skin cancer
Skin Neoplasms - pathology
Skin Neoplasms - surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sentinel lymph node biopsy (SLNB) is a surgical procedure that has been used in patients with cutaneous melanoma for nearly 30 years. It is used for both staging and regional disease control with minimum morbidity, as proven by numerous worldwide prospective studies. It has been incorporated in the recommendations of national and professional guidelines. In this article, we provide a summary of the general information on SLNB in the clinical guidelines for the management of cutaneous malignant melanoma (American Association of Dermatology, European Society of Medical Oncology, National Comprehensive Cancer Network, and Cancer Council Australia) and review the most relevant literature to provide an update on the existing recommendations for SLNB.
ISSN:1648-9144
1010-660X
1648-9144
DOI:10.3390/medicina58111589